Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 512

1.

Durable response after cessation of anti-programmed death 1 therapy in four melanoma patients.

Handa T, Kato J, Sumikawa Y, Hida T, Horimoto K, Sato S, Sawada M, Fujioka M, Minowa T, Matsui Y, Uhara H.

J Dermatol. 2019 Oct 3. doi: 10.1111/1346-8138.15095. [Epub ahead of print] No abstract available.

PMID:
31583754
2.

Clinicopathological Features, Surgical Outcomes, Oncogenic Status and PD-L1 Expression of Pulmonary Pleomorphic Carcinoma.

Nakanishi K, Sakakura N, Matsui T, Ueno H, Nakada T, Oya Y, Shimizu J, Hida T, Hosoda W, Kuroda H.

Anticancer Res. 2019 Oct;39(10):5789-5795. doi: 10.21873/anticanres.13782.

PMID:
31570483
3.

Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.

Takeda M, Ohe Y, Horinouchi H, Hida T, Shimizu J, Seto T, Nosaki K, Kishimoto T, Miyashita I, Yamada M, Kaneko Y, Morimoto C, Nakagawa K.

Lung Cancer. 2019 Sep 16;137:64-70. doi: 10.1016/j.lungcan.2019.09.010. [Epub ahead of print]

4.

[A Case of Ureteral Sciatic Hernia Treated with Ureteral Stent].

Hattori Y, Hida T, Nakamura K, Takahashi T, Mitsumori K, Ohnishi H.

Hinyokika Kiyo. 2019 Jul;65(7):295-298. doi: 10.14989/ActaUrolJap_65_7_295. Japanese.

PMID:
31501395
5.

Uptake of 18F-FDG in Adrenal Adenomas Is Associated With Unenhanced CT Value and Constituent Cells.

Murayama R, Nishie A, Hida T, Baba S, Inokuchi J, Oda Y, Honda H.

Clin Nucl Med. 2019 Sep 4. doi: 10.1097/RLU.0000000000002759. [Epub ahead of print]

PMID:
31490313
6.

Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.

Horinouchi H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Saka H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Sumiyoshi N, Tamura T.

Cancer Med. 2019 Sep;8(11):5183-5193. doi: 10.1002/cam4.2411. Epub 2019 Jul 29.

7.

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.

Dietel M, Savelov N, Salanova R, Micke P, Bigras G, Hida T, Antunez J, Guldhammer Skov B, Hutarew G, Sua LF, Akita H, Chan OSH, Piperdi B, Burke T, Khambata-Ford S, Deitz AC.

Lung Cancer. 2019 Aug;134:174-179. doi: 10.1016/j.lungcan.2019.06.012. Epub 2019 Jun 12.

PMID:
31319978
8.

Successful salvage surgery following multimodal therapy in a patient who harboured ALK-rearranged advanced lung adenocarcinoma with multiple organ metastases.

Horio Y, Mizuno T, Sakao Y, Inaba Y, Yatabe Y, Hida T.

Respirol Case Rep. 2019 Jun 24;7(7):e00451. doi: 10.1002/rcr2.451. eCollection 2019 Oct.

9.

Minimum structural requirements for inhibitors of the zinc finger protein TRAF6.

Radwan MO, Koga R, Hida T, Ejima T, Kanemaru Y, Tateishi H, Okamoto Y, Inoue JI, Fujita M, Otsuka M.

Bioorg Med Chem Lett. 2019 Aug 15;29(16):2162-2167. doi: 10.1016/j.bmcl.2019.06.050. Epub 2019 Jun 27.

PMID:
31272791
10.

Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.

Hirashima T, Satouchi M, Hida T, Nishio M, Kato T, Sakai H, Imamura F, Kiura K, Okamoto I, Kasahara K, Uchida H, Vowler SL, Mitsudomi T.

Cancer Sci. 2019 Sep;110(9):2884-2893. doi: 10.1111/cas.14120. Epub 2019 Aug 1.

11.

[A Case of Late Onset Nivolumab-Induced Interstitial Nephritis in a Patient with Metastatic Renal Cell Carcinoma].

Hattahara K, Yamasaki T, Sawada A, Tanigaki K, Endo S, Teramoto Y, Banno H, Fuchigami Y, Suzuki R, Fujiwara M, Hida T, Yoshino T, Kita Y, Goto T, Akamatsu S, Saito R, Kobayashi T, Inoue T, Ogawa O.

Hinyokika Kiyo. 2019 May;65(5):157-161. doi: 10.14989/ActaUrolJap_65_5_157. Japanese.

PMID:
31247693
12.

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).

Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Hirano J, Namba Y, Ohe Y.

Clin Cancer Res. 2019 Sep 15;25(18):5485-5492. doi: 10.1158/1078-0432.CCR-19-0103. Epub 2019 Jun 4.

PMID:
31164373
13.

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N.

Lung Cancer. 2019 Jun;132:126-131. doi: 10.1016/j.lungcan.2019.04.014. Epub 2019 Apr 10.

14.

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study.

Katsuya Y, Horinouchi H, Seto T, Umemura S, Hosomi Y, Satouchi M, Nishio M, Kozuki T, Hida T, Sukigara T, Nakamura K, Kuchiba A, Ohe Y.

Eur J Cancer. 2019 May;113:78-86. doi: 10.1016/j.ejca.2019.03.012. Epub 2019 Apr 13.

15.

Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib.

Hida T, Dahlberg SE, Lydon CA, Hatabu H, Johnson BE, Awad MM, Nishino M.

J Thorac Imaging. 2019 Apr 12. doi: 10.1097/RTI.0000000000000413. [Epub ahead of print]

PMID:
30985604
16.

Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome.

Araki T, Dahlberg SE, Hida T, Lydon CA, Rabin MS, Hatabu H, Johnson BE, Nishino M.

Eur J Radiol Open. 2019 Mar 29;6:128-131. doi: 10.1016/j.ejro.2019.03.003. eCollection 2019.

17.

Time-resolved quantitative evaluation of diaphragmatic motion during forced breathing in a health screening cohort in a standing position: Dynamic chest phrenicography.

Hida T, Yamada Y, Ueyama M, Araki T, Nishino M, Kurosaki A, Jinzaki M, Honda H, Hatabu H, Kudoh S.

Eur J Radiol. 2019 Apr;113:59-65. doi: 10.1016/j.ejrad.2019.01.034. Epub 2019 Jan 31.

18.

Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study.

Niho S, Hosomi Y, Okamoto H, Nihei K, Tanaka H, Hida T, Umemura S, Goto K, Akimoto T, Ohe Y.

Jpn J Clin Oncol. 2019 Jul 1;49(7):614-619. doi: 10.1093/jjco/hyz039.

PMID:
30916304
19.

Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.

Yoshimura M, Kinoshita Y, Hamasaki M, Matsumoto S, Hida T, Oda Y, Iwasaki A, Nabeshima K.

Lung Cancer. 2019 Apr;130:187-193. doi: 10.1016/j.lungcan.2019.02.004. Epub 2019 Feb 27.

PMID:
30885343
20.

Current clinical issue of skin lesions in patients with inflammatory bowel disease.

Iida T, Hida T, Matsuura M, Uhara H, Nakase H.

Clin J Gastroenterol. 2019 Mar 5. doi: 10.1007/s12328-019-00958-y. [Epub ahead of print] Review.

PMID:
30838512
21.

Docetaxel therapy for classic Kaposi's sarcoma.

Hosokawa Y, Kato J, Hida T, Horimoto K, Sato S, Sawada M, Sasaki H, Matsui Y, Handa T, Uhara H.

Asia Pac J Clin Oncol. 2019 Jun;15(3):181-182. doi: 10.1111/ajco.13139. Epub 2019 Feb 21. No abstract available.

PMID:
30790461
22.

Anaplastic lymphoma kinase expression in small-cell lung cancer.

Kondoh C, Horio Y, Hayashi Y, Ebi H, Hida T, Hasegawa Y, Yatabe Y.

Histopathology. 2019 Jul;75(1):20-28. doi: 10.1111/his.13842. Epub 2019 May 23.

PMID:
30790327
23.

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.

Nishio M, Murakami H, Ohe Y, Hida T, Sakai H, Kasahara K, Imamura F, Baba T, Kubota K, Hosomi Y, Shimokawa T, Hayashi H, Miyadera K, Tamura T.

Invest New Drugs. 2019 Feb 21. doi: 10.1007/s10637-019-00732-4. [Epub ahead of print]

PMID:
30790152
24.

Decreased and slower diaphragmatic motion during forced breathing in severe COPD patients: Time-resolved quantitative analysis using dynamic chest radiography with a flat panel detector system.

Hida T, Yamada Y, Ueyama M, Araki T, Nishino M, Kurosaki A, Jinzaki M, Honda H, Hatabu H, Kudoh S.

Eur J Radiol. 2019 Mar;112:28-36. doi: 10.1016/j.ejrad.2018.12.023. Epub 2019 Jan 4.

25.

Sarcopenia affects conservative treatment of osteoporotic vertebral fracture.

Iida H, Sakai Y, Watanabe T, Matsui H, Takemura M, Matsui Y, Harada A, Hida T, Ito K, Ito S.

Osteoporos Sarcopenia. 2018 Sep;4(3):114-117. doi: 10.1016/j.afos.2018.09.002. Epub 2018 Sep 26.

26.

Utility of the Serum Cystatin C Level for Diagnosis of Osteoporosis among Middle-Aged and Elderly People.

Tanaka S, Ando K, Kobayashi K, Hida T, Ito K, Tsushima M, Morozumi M, Machino M, Ota K, Suzuki K, Seki T, Ishiguro N, Hasegawa Y, Imagama S.

Biomed Res Int. 2019 Jan 16;2019:5046852. doi: 10.1155/2019/5046852. eCollection 2019.

27.

A case of childhood-onset cutaneous mastocytosis with loss of wild-type KIT allele.

Hida T, Okura M, Kamiya T, Yamamoto M, Hori T, Uhara H.

J Eur Acad Dermatol Venereol. 2019 Jun;33(6):e235-e237. doi: 10.1111/jdv.15501. Epub 2019 Mar 11. No abstract available.

PMID:
30773694
28.

Increasing postural sway in balance test is related to locomotive syndrome risk: A cross-sectional study.

Tanaka S, Ando K, Kobayashi K, Hida T, Seki T, Hamada T, Ito K, Tsushima M, Morozumi M, Machino M, Ota K, Ishiguro N, Hasegawa Y, Imagama S.

J Orthop Sci. 2019 Sep;24(5):912-917. doi: 10.1016/j.jos.2019.01.011. Epub 2019 Feb 14.

PMID:
30773352
29.

Efficacy of combined radiotherapy and anti-programmed death 1 therapy in acral and mucosal melanoma.

Kato J, Hida T, Someya M, Sato S, Sawada M, Horimoto K, Fujioka M, Minowa T, Matsui Y, Tsuchiya T, Kitagawa M, Nakata K, Sakata KI, Torigoe T, Uhara H.

J Dermatol. 2019 Apr;46(4):328-333. doi: 10.1111/1346-8138.14805. Epub 2019 Feb 13.

PMID:
30758859
30.

Salvage surgery for small cell lung cancer after chemoradiotherapy.

Nakanishi K, Mizuno T, Sakakura N, Kuroda H, Shimizu J, Hida T, Yatabe Y, Sakao Y.

Jpn J Clin Oncol. 2019 Apr 1;49(4):389-392. doi: 10.1093/jjco/hyz010.

PMID:
30753585
31.

Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality.

Putman RK, Gudmundsson G, Axelsson GT, Hida T, Honda O, Araki T, Yanagawa M, Nishino M, Miller ER, Eiriksdottir G, Gudmundsson EF, Tomiyama N, Honda H, Rosas IO, Washko GR, Cho MH, Schwartz DA, Gudnason V, Hatabu H, Hunninghake GM.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):175-183. doi: 10.1164/rccm.201809-1652OC.

PMID:
30673508
32.

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).

Halmos B, Tan EH, Soo RA, Cadranel J, Lee MK, Foucher P, Hsia TC, Hochmair M, Griesinger F, Hida T, Kim E, Melosky B, Märten A, Carcereny E.

Lung Cancer. 2019 Jan;127:103-111. doi: 10.1016/j.lungcan.2018.10.028. Epub 2018 Nov 2.

33.

Importance of avoiding surgery delays after initial discovery of suspected non-small-cell lung cancer in clinical stage IA patients.

Kuroda H, Sugita Y, Ohya Y, Yoshida T, Arimura T, Sakakura N, Hida T, Yatabe Y, Sakao Y.

Cancer Manag Res. 2018 Dec 20;11:107-115. doi: 10.2147/CMAR.S180757. eCollection 2019.

34.

<Editors' Choice> Ultrasound measurement of thigh muscle thickness for assessment of sarcopenia.

Hida T, Ando K, Kobayashi K, Ito K, Tsushima M, Kobayakawa T, Morozumi M, Tanaka S, Machino M, Ota K, Kanbara S, Ito S, Ishiguro N, Hasegawa Y, Imagama S.

Nagoya J Med Sci. 2018 Nov;80(4):519-527. doi: 10.18999/nagjms.80.4.519.

35.

Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.

von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han JY, Hida T, Moro-Sibilot D, Conkling P, Gandara DR, Rittmeyer A, Gandhi M, Yu W, Matheny C, Patel H, Sandler A, Ballinger M, Kowanetz M, Park K.

Eur J Cancer. 2019 Jan;107:124-132. doi: 10.1016/j.ejca.2018.11.020. Epub 2018 Dec 17.

PMID:
30562710
36.

Increased Airway Wall Thickness in Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis.

Miller ER, Putman RK, Diaz AA, Xu H, San José Estépar R, Araki T, Nishino M, Poli de Frías S, Hida T, Ross J, Coxson H, Dupuis J, O'Connor GT, Silverman EK, Rosas IO, Hatabu H, Washko G, Hunninghake GM.

Ann Am Thorac Soc. 2019 Apr;16(4):447-454. doi: 10.1513/AnnalsATS.201806-424OC.

PMID:
30543456
37.

Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm.

Nishino M, Wakai S, Hida T, Dahlberg SE, Ozaki M, Hatabu H, Tachizaki H, Johnson BE.

Eur J Radiol. 2018 Dec;109:68-76. doi: 10.1016/j.ejrad.2018.10.014. Epub 2018 Oct 23.

PMID:
30527314
38.

Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.

Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G.

Cancer. 2019 Mar 15;125(6):892-901. doi: 10.1002/cncr.31891. Epub 2018 Dec 4.

PMID:
30512189
39.

Halo formations around senile hemangiomas in diffuse plane normolipemic xanthomatosis associated with monoclonal gammopathy.

Hida T, Takahashi H, Takada K, Uhara H.

JAAD Case Rep. 2018 Nov 10;4(10):1034-1036. doi: 10.1016/j.jdcr.2018.08.012. eCollection 2018 Nov. No abstract available.

40.

Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.

Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Yatabe Y, Hida T.

Lung Cancer. 2018 Nov;125:212-217. doi: 10.1016/j.lungcan.2018.10.001. Epub 2018 Oct 3.

PMID:
30429022
41.

Detection of abundant megakaryocytes in pulmonary artery blood in lung cancer patients using a microfluidic platform.

Dejima H, Nakanishi H, Kuroda H, Yoshimura M, Sakakura N, Ueda N, Ohta Y, Tanaka R, Mori S, Yoshida T, Hida T, Sawabata N, Yatabe Y, Sakao Y.

Lung Cancer. 2018 Nov;125:128-135. doi: 10.1016/j.lungcan.2018.09.011. Epub 2018 Sep 16.

PMID:
30429010
42.

Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma.

Kamiya S, Kato J, Kamiya T, Yamashita T, Sumikawa Y, Hida T, Horimoto K, Sato S, Takahashi H, Sawada M, Kubo T, Torigoe T, Uhara H.

Asia Pac J Clin Oncol. 2018 Nov 8. doi: 10.1111/ajco.13102. [Epub ahead of print]

PMID:
30411509
43.

Prognostic role of platelet to lymphocyte and lymphocyte to monocyte ratios in advanced melanoma treated with anti-programmed death-1.

Minowa T, Kato J, Hida T, Horimoto K, Sato S, Sawada M, Uhara H.

Eur J Dermatol. 2018 Oct 1;28(5):705-707. doi: 10.1684/ejd.2018.3381. No abstract available.

PMID:
30406759
44.

Nevus cells of cardiofaciocutaneous syndrome bear BRAF germ-line and somatic double mutations.

Hida T, Sato S, Okura M, Uhara H.

Eur J Dermatol. 2018 Oct 1;28(5):704-705. doi: 10.1684/ejd.2018.3375. No abstract available.

PMID:
30406758
45.

Impact of body mass index on CT attenuation of adrenal adenoma.

Nishie A, Asayama Y, Ishigami K, Ushijima Y, Kakihara D, Nakayama T, Fujita N, Morita K, Ishimatsu K, Takao S, Hida T, Sugimoto M, Honda H.

Eur J Radiol. 2018 Nov;108:184-188. doi: 10.1016/j.ejrad.2018.09.033. Epub 2018 Oct 2.

PMID:
30396653
46.

[Right Essential Renal Hematuria that Can Not Be Coagulated with a Ureteroscope Treated by Hydrogen Peroxide Instillation : A Case Report].

Hida T, Hattori Y, Nakamura K, Kohno J, Okubo K, Takahashi T, Mitsumori K, Nishimura K, Ohnishi H.

Hinyokika Kiyo. 2018 Aug;64(8):335-338. doi: 10.14989/ActaUrolJap_64_8_335. Review. Japanese.

47.
48.

Electrophysiological Function of the Lumbar Multifidus and Erector Spinae Muscles in Elderly Patients With Chronic Low Back Pain.

Sakai Y, Matsui H, Ito S, Hida T, Ito K, Koshimizu H, Harada A.

Clin Spine Surg. 2019 Feb;32(1):E13-E19. doi: 10.1097/BSD.0000000000000709.

PMID:
30247186
49.

Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer: A case report.

Oya Y, Yoshida T, Uemura T, Murakami Y, Inaba Y, Hida T.

Oncol Lett. 2018 Oct;16(4):4219-4222. doi: 10.3892/ol.2018.9158. Epub 2018 Jul 17.

50.

Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment.

Furuta H, Uemura T, Yoshida T, Kobara M, Yamaguchi T, Watanabe N, Shimizu J, Horio Y, Kuroda H, Sakao Y, Yatabe Y, Hida T.

Anticancer Res. 2018 Sep;38(9):5231-5237. doi: 10.21873/anticanres.12847.

PMID:
30194172

Supplemental Content

Support Center